Metformin Effective in Osteoarthritis The diabetes drug metformin provided overweight/obese patients with osteoarthritis (OA) of the knee with significantly greater pain relief than did placebo in a small randomized trial, researchers said. https://t.co/7krvFFfRFC https://t.co/g1UyNjazUv

• Metformin Effective in Osteoarthritis | RheumNow

Inflammatory vs. Noninflammatory Pain https://t.co/ZZLMnT8IVO https://t.co/AqqonM6Vht

• Inflammatory vs. Noninflammatory Pain | RheumNow

No Extra Cancer Recurrence Risk with Biologics in RA Rheumatoid arthritis (RA) patients in Denmark with a history of solid tumor cancers, now in remission, faced no greater likelihood of cancer relapse when they were treated with biologic agents, compared with conventional https://t.co/dCspjN2oys

Tuesday Night Rheumatology returns this month with the launch of Lupus Unlocked, starting with a special Journal Club session. Join authors Dr. Richard Furie and Dr. Brad Rovin as they walk us through their pivotal studies on lupus nephritis: 📄 Obinutuzumab in Active Lupus https://t.co/PdhC857sfX

Retrospective Medicare Claims data study of RA pts w/ metastatic non-small cell lung cancer who recv Rx w/ immune checkpoint inhibitor; found that ICI- Rx RA had the same survival as non-RA pts, and sterid use was not associated with worse survival https://t.co/JLlCfrRwvN https://t.co/zeqeYt5ZHq

• Survival in immune checkpoint inhibitor‐treated patients with rheumatoid arthri…

Complex Evolution of RA Management and Outcomes FIRST is a Japanese longitudinal, real-world registry of rheumatoid arthritis (RA) management, and over the last 20 years has shown significantly improved outcomes, yet significant challenges and unmet needs remain. https://t.co/TwDIf5MJqF

FDA has approved nipocalimab (Imaavytm), a FcRn for use in generalized myasthenia gravis (gMG). It is approved for using in gMG patents who are anti-AChR and anti-MuSK antibody positive adults and pediatric gMG patients aged 12 and older. https://t.co/CaSwCnCK8V https://t.co/A2COjk2hzY

• Johnson & Johnson receives FDA approval for IMAAVYTM (nipocalimab-aahu), a new …

EULAR Guidelines on Reproductive Health Rheumatology patients considering or actually having babies can safely take most of the medications currently used to treat their conditions, according to an updated guideline from the European Alliance of Associations for Rheumatology https://t.co/121I7Yb8Ki

67 systemic sclerosis pts w/ mod-to-severe lower GI Sxs were Rx in phase 2, RDBPCT of placebo or fecal transplants at wks 0 and 2, with no signif change in GI sxs by week 12 (bloating or diarrhoea). https://t.co/vWq2c8d4Kn https://t.co/EZGgVYpxAl

• Faecal microbiota transplantation in patients with systemic sclerosis and lower…

Review of SARCOPENIA - a loss of muscle mass and function, with significant implications on physical performance. More common in RA, SSc, SpA, SLE, FM, myositis, and vasculitis https://t.co/tCXdoEn9xR https://t.co/Oi91niMn5M

• Sarcopenia in Rheumatic Diseases: A Hidden Issue of Concern

45 southern African American SLE pts compared to multiethnic cSLE, AA pts had signif higher Dz activity & greater damage accrual. Their mean SLICC score was 8.4, SLEDAI 13, but was 7.4 @6 mos & 4,7 @1 yr. They traveled an avg distance 75 miles to see Rheum https://t.co/NMlT4uo8jn https://t.co/uG5ofMGE6O

• Characterizing lupus in African American children in Southern United States - P…

FDA Approves Rinvoq for Giant Cell Arteritis Based on the results of the SELECT-GCA study, the US FDA has approved upadacitinib (Rinvoq or UPA) for the treatment of adults with giant cell arteritis (GCA), also known as temporal arteritis. This is the 9th FDA approved indication https://t.co/gPTwnR2VLw